Obeticholic acid (OCA), a BA FXR agonist, has been developed as a candidate medication for NAFLD therapy (Wang et al., 2024; Ahmed et al., 2022). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.